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ABSTRACT
Breast cancer patients who initially respond to cancer therapies often succumb
to distant recurrence of the disease. It is not clear why people with the same type
of breast cancer respond to treatments differently; some escape from dormancy and
relapse earlier than others. In addition, some tumor clones respond to immunotherapy
while others do not. We investigated how autophagy plays a role in accelerating
or delaying recurrence of neu-overexpressing mouse mammary carcinoma (MMC)
following adriamycin (ADR) treatment, and in affecting response to immunotherapy.
We explored two strategies: 1) transient blockade of autophagy with chloroquine (CQ),
which blocks fusion of autophagosomes and lysosomes during ADR treatment, and 2)
permanent inhibition of autophagy by a stable knockdown of ATG5 (ATG5KD), which
inhibits the formation of autophagosomes in MMC during and after ADR treatment.
We found that while CQ prolonged tumor dormancy, but that stable knockdown of
autophagy resulted in early escape from dormancy and recurrence. Interestingly,
ATG5KD MMC contained an increased frequency of ADR-induced polyploid-like cells and
rendered MMC resistant to immunotherapy. On the other hand, a transient blockade of
autophagy did not affect the sensitivity of MMC to immunotherapy. Our observations
suggest that while chemotherapy-induced autophagy may facilitate tumor relapse,
cell-intrinsic autophagy delays tumor relapse, in part, by inhibiting the formation of
polyploid-like tumor dormancy.

INTRODUCTION

autophagy has a cancer-promoting role by protecting
tumor cells from chemotherapy or providing a source
of energy for tumor cells to survive under hypoxic and
acidic conditions despite the lack of mature vessels [1].

Autophagy plays a paradoxical role in the
promotion and inhibition of cancer. On the one hand,
www.oncotarget.com
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A transient blockade of autophagy by CQ during
ADR treatment delays tumor relapse in vitro but
not in vivo

On the other hand, inhibition of autophagy by disruption
of Beclin 1 or deletion of ATG5 increases the frequency
of spontaneous malignancies [2] or liver tumor [3],
respectively. Recently, four different mechanisms have
been proposed to describe paradoxical functions of
autophagy in cancer, which include cytotoxic, cytostatic,
cytoprotective and non-protective autophagy [4]. There
are also three major types of autophagy which include
micro-autophagy involving the direct engulfment of
cytosolic material by lysosomes through invagination,
chaperone-mediated autophagy involving HSP70 and the
lysosomal membrane associated protein 2 A (LAMP2A),
and macro-autophagy which is a highly conserved
pathway involving the formation of autophagosomes,
which fuse with lysosomes. To this end, ATG5 is
involved in the elongation of autophagosomes to engulf
toxic material for degradation. A stable knockdown
of ATG5 results in the inhibition of the formation of
autophagosomes and progression of macro-autophagy
[5]. Chloroquine (CQ), on the other hand, does not have
any effects on autophagosomes but it blocks the fusion of
autophagosomes and lysosomes, thereby preventing the
completion of macro-autophagy. In order to investigate
the role of macro-autophagy in tumor dormancy and
relapse, we performed a transient inhibition of macroautophagy by means of CQ during chemotherapy,
which mainly inhibits chemotherapy-induced autophagy
while cell-intrinsic autophagy will be restored after
the completion of chemotherapy. We also performed a
permanent inhibition of cell-intrinsic macro-autophagy
by a stable knockdown of ATG5 in tumor cells. We
demonstrated that cell-intrinsic, but not chemotherapyinduced, autophagy can inhibit tumor relapse.

Since CQ is being used to sensitize tumor cells
susceptible to chemotherapy [6], we sought to determine
whether blockade of autophagy by CQ during ADR
treatment affects tumor dormancy and relapse. We showed
that the presence of CQ during ADR treatment, in vitro,
resulted in prolonging tumor dormancy such that, while
ADR treated MMC resumed cell proliferation 6 weeks after
the treatment, ADR+CQ treated MMC remained dormant
(Figure 2A). In order to confirm tumor cell relapse after 6
weeks, flow cytometry analysis of ADR-treated MMC was
performed, and indicated a shift of Ki67- non-proliferating
cells to Ki67+ proliferating cells with a greater viability
(Figure 2B). In fact, MMC cells remained apoptotic by
producing floater dead cells following ADR treatment
(Supplementary Figure 1A) which compensated for cell
proliferation and maintained tumor dormancy for 3 weeks
after the completion of ADR treatment. Follow up studies on
floater cells showed they were all apoptotic (Supplementary
Figure 1B). A transient blockade of autophagy by CQ did
not affect susceptibility of tumor cells to ADR-induced
apoptosis (Supplementary Figure 2). On the other hand, a
transient blockade of autophagy during ADR chemotherapy,
in vivo, did not prolong tumor dormancy in FVBN202 mice
(Supplementary Figure 3).

A transient blockade of autophagy by CQ during
ADR treatment does not change susceptibility of
tumor cell to immunotherapy
In order to determine whether a transient blockade
of autophagy during ADR treatment affects susceptibility
of dormant MMC to immunotherapy, dormant MMC were
cultured with either IFN-γ or MMC-reactive T cells three
weeks after treatment with ADR or ADR+CQ. As shown
in Figure 3, untreated MMC or dormant MMC treated
with ADR or ADR+CQ all remained susceptible to IFN-γ
treatment or T cells.

RESULTS
Adriamycin induces autophagy in MMC
In order to determine whether ADR induces
autophagy and in turn establishes tumor dormancy, MMC
cells were treated with ADR in the presence or absence of
CQ, a pharmacological agent used to block the final stages
of autophagy, specifically the fusion of autophagosomes
with lysosomes that is necessary for digestion of the cargo
in the autophagosomes (frequently termed “autophagic
flux”). CQ blocked this autophagic flux as evidenced by
the enhanced accumulation of acidic vesicles (red signals)
(Figure 1A, ADR and ADR+CQ). We further monitored
degradation of the p62/SQSTM1 protein as a marker of
autophagic flux, and LC.3B expression as a marker of
autophagosomes formation (since LC3 is a component
of the autophagosomes). As shown in Figure 1B, ADR
did not induce degradation of p62/SQSTM1 although it
elevated LC.3B, suggesting that ADR induces autophagy
but fails to drive autophagy to completion and p62/
SQSTM1 degradation.
www.oncotarget.com

A stable knockdown of autophagy reduces
susceptibility of MMC to ADR treatment
CQ only transiently blocks fusion of autophagosomes
and lysosomes during ADR treatment such that after
removal of CQ, accumulated autophagosomes could
eventually be fused with lysosomes to complete
autophagy. In order to determine the role of autophagy in
tumor dormancy or relapse, we used shRNA for a stable
knockdown of ATG5 (ATG5KD) which inhibits formation
of autophagosomes in MMC. Scrambled shRNA was used
as control (Supplementary Figure 4A). The ATG5KD MMC
and scrambled control MMC were irradiated to confirm that
ATG5KD MMC cells were deficient in autophagy, using p62
2
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and LC.3B as read outs (Supplementary Figure 4B). Tumor
cells remained intact for the expression of neu antigen,
as well as cell proliferation in vitro and in vivo following
knockdown of autophagy (Supplementary Figure 4C–4E).
Flow cytometry analysis determined a lower level of
viability in MMC compared with ATG5KD MMC following
ADR treatment (Figure 4).

challenged with ADR-treated MMC. Hematoxylin/eosin
and immunohistochemistry analyses of tumor lesions
determined a higher frequency of polyploid-like and Ki67+
tumor cells in animals that were challenged with ADRtreated ATG5KD MMC (Figure 6B). Finally, ATG5KD MMC
were found to be resistant to T cell-induced apoptosis
compared with autophagy-competent MMC (Figure 7).

A stable knockdown of autophagy results in
earlier tumor relapse associated with increased
frequency of polyploid-like cells and resistance to
immunotherapy

DISCUSSION
Cell-intrinsic autophagy is an ongoing process, which
regulates cellular metabolism and homeostasis. Autophagy
is also induced by insults such as chemotherapy. Here, we
studied a paradoxical role of autophagy in tumor promotion
and tumor inhibition by a transient inhibition of autophagy
only during chemotherapy or a stable knockdown of
autophagy in MMC tumor cells. While the former
transiently blocked autophagy and cell-intrinsic autophagy
was restored after the completion of chemotherapy,
the latter permanently blocked chemotherapy-induced
autophagy and cell-intrinsic autophagy. We demonstrated
that inhibition of chemotherapy-induced autophagy
by CQ did not increase susceptibility of tumor cells
to chemotherapy-induced apoptosis. Nevertheless,
chemotherapy-induced autophagy appeared to accelerate
tumor relapse such that use of CQ during chemotherapy
delayed tumor relapse in vitro. Our observation is
consistent with other reports showing that increased
autophagy in residual breast cancer after neoadjuvant
chemotherapy was correlated with increased risk of tumor
relapse [7]. A transient blockade of autophagy during
chemotherapy of tumor-bearing animals did not affect
tumor relapse, perhaps, because tumor inhibitory effects of
in vivo chemotherapy was not as effective as in vitro drug
treatment. Also, chemotherapy-induced autophagy did not
affect the sensitivity of tumor cells to apoptosis induced by
IFN-γ or tumor-reactive T cells.

In order to determine whether a higher viability
of ATG5KD MMC following ADR treatment (Figure 4)
facilitates an earlier tumor relapse compared with wild
type MMC, follow up studies were performed for three
weeks after ADR treatment. As shown in Figure 5A,
ATG5KD MMC survived better than autophagy-competent
MMC following ADR treatment showing a significantly
higher number of cells by 3 weeks after the treatment.
Flow cytometry analysis of tumor cells showed greater
levels of apoptosis in wild type MMC compared with
ATG5KD MMC (Figure 5B, p < 0.001). Interestingly,
ATG5KD MMC cells contained a higher number of
polyploid-like cells following ADR treatment compared
with autophagy-competent MMC (Figure 5B, p < 0.03).
In order to determine the in vivo relevance of our
in vitro findings, FVBN202 mice were used. Tumor
dormancy was first established by ADR treatment in vitro;
FVBN202 mice (n = 7/group) were then challenged i.v.
with one million viable dormant tumor cells. Animals
were then sacrificed when they became moribund (lost
10% weight) as a result of massive lung metastasis. As
can be seen in Figure 6A, animals that were challenged
with ADR-treated ATG5KD MMC developed lung
metastasis significantly sooner than those that were

Figure 1: CQ blocks ADR-induced autophagy. MMC tumor cells received three daily doses of ADR alone (1 µM ADR for 2 hrs)

(ADR) or in the presence of CQ (10 µM 3 hrs before ADR and 2 hrs during ADR treatment) (ADR+CQ), washed after each daily treatment
and analyzed by acridine orange (AO) one day after the last treatment. Untreated MMC (Medium) or MMC treated with CQ (CQ) served
as controls. (A) Acridine orange (AO) staining was analyzed for acidic vesicles (red) using image cytometry. Data represent triplicate
experiments. (B) Levels of p62/SQSTM1 and LC.3B after treatment with ADR ± CQ indicative of autophagy induction in the absence of
autophagic flux (B).
www.oncotarget.com
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We also demonstrated that, unlike chemotherapyinduced autophagy, cell-intrinsic autophagy accelerated
tumor relapse. A stable knockdown of cell-intrinsic
autophagy by ATG5 shRNA resulted in a reduced
sensitivity of tumor cells to chemotherapy- or T cellinduced apoptosis, and accelerated tumor relapse
in vivo. These effects coincided with an increased
frequency of multinuclear polyploid-like dormant cells.
These observations suggest that chemotherapy-induced
autophagy could have tumor-promoting effects and
facilitate tumor relapse, whereas cell-intrinsic autophagy
could synergize with cancer therapeutics and delay tumor
relapse. In fact, cell-intrinsic autophagy would seem
to inhibit the formation of multinuclear cells following
chemotherapy, and to prevent chemotherapy-induced
genetic instability associated with resistance to cancer
therapeutics. Similar observations have been made in
other breast tumor models by showing that CQ but not
knockdown of Beclin 1 or ATG12 sensitized the tumor
to chemotherapy [8]. Therefore, anti-tumor effects of

autophagy inhibitors such as CQ is likely to be because
of the inhibition of chemotherapy-induced autophagy
while anti-tumor effects of autophagy inducers such
as rapamycin may result from enhanced cell-intrinsic
autophagy [9, 10]. It has been reported cancer stem cells
play a role in tumor dormancy [11] and drug resistance
[12], and that immunotherapeutic targeting of breast
cancer stem cells inhibits growth of mammary carcinoma
[13]. However, we did not detect the enrichment of
CD44+CD24- cancer stem cells following ADR-induced
tumor dormancy (data not shown).
Anticancer drugs and ionizing radiation tend
to induce autophagy in tumor cells [14]. Treatmentinduced autophagy could lead to apoptosis [15] and
tumor cell dormancy [16]. We have already reported that
dormant tumor cells established by ADR treatment or
radiation therapy, in vitro, developed resistance to these
treatments but remained susceptible to immunotherapy
[17]. Therefore, evaluation of apoptosis or tumor
growth inhibition as a single factor without evaluating

Figure 2: ADR-induced dormant tumor cells remain dormant in the presence of CQ. MMC tumor cells were treated with 3

daily doses of ADR (1 uM for 2 hrs), with one group receiving CQ (10 uM) 3 hrs prior to and during ADR treatment. Both groups remained
untreated for 3 weeks and 6 weeks, in vitro. (A) Adherent viable cells were counted using trypan blue exclusion at various time points.
Data represent 3 replicates ± SEM. (B) At weeks 3 and 6 post-treatment, Ki-67 expression (upper panel) and viability (lower panel) were
quantified within the population of adherent tumor cells. Data represent 2–3 replicates ± SEM. Four independent experiments have been
carried out which have shown similar results.
www.oncotarget.com
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Figure 3: Dormant tumor cells established by ADR or ADR+CQ remain susceptible to immunotherapy. The in vitro

tumor dormancy was established three weeks after three daily treatments of MMC with ADR or ADR+CQ. Untreated MMC cells were used
as control. (A) Apoptosis was determined by FVS viability staining in MMC (control), ADR-treated dormant MMC (ADR), ADR+CQtreated dormant MMC (ADR+CQ), as well as control MMC cultured with three daily doses of IFN-g and analyzed two days later (50
ng/ml) (IFN-g), ADR-treated dormant MMC cultured with three daily doses of IFN-g (50 ng/ml) and analyzed two days later (ADR >
IFN-g), or ADR+CQ-treated dormant MMC cultured with three daily doses of IFN-g (50 ng/ml) and analyzed two days later (ADR+CQ
> IFN-g). (B) Apoptosis was determined by FVS viability staining of MMC (control), MMC cultured with MMC-sensitized T cells for 48
hrs (T cells), ADR-treated dormant MMC (ADR), ADR-treated dormant MMC cultured with MMC-sensitized T cells for 48 hrs (ADR > T
cells), ADR+CQ-treated dormant MMC (ADR+CQ), or ADR+CQ-treated dormant MMC cultured with MMC-sensitized T cells for 48 hrs
(ADR+CQ > T cells). Splenic T cells were collected from MMC tumor-bearing FVBN202 mice.

Figure 4: Autophagy knockdown tumor cells become less susceptible to ADR-induced apoptosis. Autophagy-deficient

MMC (ATG5KD MMC) or autophagy-competent MMC (MMC) were treated with a single dose of ADR alone (1 uM ADR for 2 hrs).
Tumor cells were analyzed by Annexin V/PI staining prior to treatment (Day 0) or three days after the treatment (Day 4). Experiments were
performed in triplicates.
www.oncotarget.com
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tumor dormancy and relapse may not be sufficient
for understanding anti-cancer efficacy of autophagy
inhibitors such as CQ. Inhibition of autophagy by CQ
during chemotherapy diminishes the expression of DNA
repair proteins, resulting in tumor growth inhibition in
carboplatin-resistant BRCA1 wild-type TNBC orthotopic
xenografts [18]. In triple negative breast cancer, CQ
sensitizes tumor cells to paclitaxel chemotherapy [19].
In several tumor models, CQ synergistically augmented
sunitinib cytotoxicity on tumor cells [6]. However, the
role of CQ in inhibiting tumor recurrence has yet to be
determined.
Cells that are deficient in autophagy show increased
levels of reactive oxygen species which result in the
accumulation of DNA damage, increased double-strand
breaks and polyploid nuclei [20, 21]. To this end,
cell-intrinsic autophagy protects the cell from genomic
instability induced by the accumulation of toxins within
the cell [22]. It has been reported that Beclin1 knockout
mice fail to maintain genomic integrity by increasing DNA
double stranded breaks and gene amplifications [20]. A
higher expression of Beclin 1 in healthy breast tissue than
in breast cancer suggests a deficiency in cell-intrinsic
autophagy in tumors [23], which could contribute to
genomic instability during tumorigenesis. In breast cancer
patients who received adjuvant chemotherapy, presence of
tumor cell intrinsic autophagy contributed to reduced risk
of tumor relapse [24]. Expression of ATG5 in the tumor
specimens is also associated with relapse-free survival
in breast cancer patients [25]. In glioma, reduced tumor
cell progression and relapse by knockdown of CDGSH
iron sulfur domain 2 (CISD2) was associated with the
activation of Beclin 1-mediated autophagy [26].
Our observations suggest that any deficiency
in tumor cell-intrinsic autophagy could result in a
reduced sensitivity of breast cancer to chemotherapy or
immunotherapy. Therefore, IHC analysis of tumor biopsies

before and after neoadjuvant or adjuvant chemotherapy
could determine cell-intrinsic and chemotherapy-induced
autophagy, respectively, and in turn might predict the risk
of distant recurrence of the diseases accordingly. In future
studies, other murine and human breast tumor cell lines
as well as other types of carcinoma cells should be used
in order to determine whether our findings offer a general
mechanism of autophagy-associated tumor dormancy and
relapse, or it might be a cancer specific phenomenon.

MATERIALS AND METHODS
Tumor cell line
The neu overexpressing mouse mammary carcinoma
(MMC) cell line was established from spontaneous
mammary tumors harvested from FVBN202 mice [27].
Tumor cells were maintained in RPMI 1640 supplemented
with 10% FBS.

Genetic silencing of ATG5 in MMC
Mission shRNA bacterial stocks for ATG5 and
scrambled Control were purchased from Sigma Aldrich.
Lentiviruses were produced in HEK 293TN cells cotransfected using Endo F ectinTM Lenti Transfection
Reagent (GeneCopoeia, 1001–01) with a packaging
mixture of psPAX2 and pMD2.G constructs (Addgene).
Media containing the viruses was used to infect MMC
cells; puromycin (1 μg/ml) was used as a selection marker
to enrich for infected cells.

Antibodies
All antibodies were purchase from Biolegend
(San Diego, CA) unless otherwise stated. Antibodies
were used as instructed by the supplier. Antibodies

Figure 5: ADR-induced tumor dormancy in autophagy knockdown tumor cells with polyploid-like morphology
compared with autophagy competent tumor cells, in vitro. MMC or ATG5KD MMC tumor cells (3 million cells, Day 0) were

treated with 3 daily doses of ADR (1uM for 2 hrs), and viable cells were counted at week 3 using trypan blue exclusion. Data represent
triplicate experiments (A). Dot plots from each experimental group gated for cell cycle phase based upon DNA content (7-AAD) and Ki-67
expression. Events falling to the left of the G1/G0 gates are considered apoptotic cells (AP). Events falling to the far right of the G2/M gate
are considered polyploid-like cells (Poly) (B). Three independent experiments have been performed and data represent 3 replicates ± SEM.
www.oncotarget.com
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Figure 6: Earlier relapse of autophagy knockdown tumor cells with polyploid morphology compared with autophagy
competent tumor cells, in vivo. (A) FVBN202 mice (n = 7) were challenged i.v. with 106 cells ADR-treated dormant control
MMC (MMC), or ADR-treated dormant ATG5KD MMC (ATG5KD MMC). Animals were euthanized as soon as they became moribund.
Representative tumor relapse in the lung and survival curve are shown. (B) Relapsed tumors were collected and immunohistochemistry
slides were prepared by either staining samples with hematoxylin and eosin (H&E) or by Ki67 staining followed by subsequent digitization
and analysis with NDP View software (Hamamatsu Photonics). At twenty-times magnification, three representative 0.02 mm2 areas were
chosen from the H&E slides containing approximately 100 cells to measure nuclear envelope size. Cells containing a nuclear envelope
equal to or greater than 16 um with visible multi-nuclei were considered polyploid-like or high grade cells. The corresponding cell was then
analyzed on the Ki67 stained slide to determine Ki67 expression levels. Data was collected from three biological samples. Significance is
based on a two-tailed t-test of p < 0.05.
www.oncotarget.com
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include: anti-CD16/32 (clone 93), APC-anti-mouse IgG
(Poly4053), PE-Ki67 (16A8), Alexa flour 488-Ki67
(11F6), Brilliant Violet 605-CD45 (30-F11), FITCAnnexin V, APC-Annexin V, 7-AAD viability staining
solution and Propidium Iodide solution (PI), mouse
anti-rat neu (anti–c-Erb2/c-Neu; 7.16.4, Calbiochem,
Billerica, MA), FITC-FVS (BD Biosciences). All
reagents were used at the manufacturer’s recommended
concentration.

weekly treatments of ADR (i.v., 9 mg/kg) or with 3 weekly
treatment of ADR + 60 mg/kg CQ (i.p.).

Cytotoxicity assay
Freshly isolated tumor-primed splenic T
cells or ex vivo expanded splenic T cells were
cultured with MMC at a 10:1 E:T ratio in 3 ml
complete medium (RPMI-1640 supplemented with
100 U/ml of penicillin, 100 µg/ml streptomycin,
10% FBS, 10 mM L-glutamine and 5 × 10–5
M 2-mercaptoethanol) with 20U/ml of IL-2 (Peprotech)
in 6 well culture dishes. After 48 hs cells were
harvested and stained for neu (anti-c-Erb2/c–Neu,
Calbiochem), Annexin V and PI according to the
manufacturer’s protocol (BD Pharmingen). Flow
cytometry was used to analyze the viability of neu
positive cells [17, 30].
IFN-γ ELISA. Reprogrammed immune cells were
cultured in complete medium with irradiated (140 Gy)
tumor cells, ADR-treated dormant MMC or ADR+CQtreated dormant MMC at a 10:1 ratio for 20 hrs.
Supernatants were then collected and stored at −80°C until
assayed. IFN-γ was detected using a Mouse IFN-γ ELISA
kit (BD Biosciences), according to the manufacturer’s
protocol [30].

Mice
FVBN202 transgenic female mice (The Jackson
Laboratory; Bar Harbor, ME) were used. These mice
overexpress non-mutated, non-activated rat neu transgene
under the regulation of the mouse mammary tumor
virus promoter [28]. These mice develop premalignant
mammary hyperplasia similar to ductal carcinoma in situ
prior to the development of spontaneous carcinoma [29].
These studies have been reviewed and approved by the
Institutional Animal Care and Use Committee at Virginia
Commonwealth University.

Experimental tumor dormancy
In vitro tumor dormancy was established by the
treatment of MMC or ATG5KD MMC tumor cells with 3 daily
doses of ADR (Sigma-Aldrich, 1uM for 2 hrs). During ADR
treatment, MMC tumor cells were cultured without or with
CQ (Sigma-Aldrich, 10 uM, 3 hrs prior to and during ADR
treatment). By 2 weeks after the treatment, all groups did not
show any increases in the number of adherent cells, which is
the characteristic of tumor dormancy. For in vivo induction
of tumor dormancy, FVBN202 mice were challenged with
ADR-treated dormant MMC or ATG5KD MMC (i.v. injection
of 1 million viable cells), or untreated MMC followed by 3

Statistical analysis
Data are summarized as means and standard errors
of the mean (SEM) with differences between groups
being illustrated with graphical data presented as mean
± SEM. Statistical comparisons were made using a onetailed or two-tailed Student t test and a p-value < 0.05 was
considered significant (*: < 0.05, **: < 0.005. ***: < 0.0005,
****
: < 0.00005).

Figure 7: Autophagy knockdown tumor cells become resistant to T cell-induced apoptosis. Neu overexpressing autophagydeficient MMC (ATG5KD MMC) or autophagy-competent MMC (MMC) were co-cultured with MMC-sensitized T cells and then gated
CD45-Neu+ tumor cells were analyzed by Annexin V/PI staining. Data represents triplicate experiments.

www.oncotarget.com

8

Oncotarget

Abbreviations

Gewirtz DA, Karantza V, Kimmelman A, Kumar S, Levine
B, et al. Autophagy in malignant transformation and cancer
progression. The EMBO journal. 2015; 34:856–880.

ADR, Adriamycin, ATG5, Autophagy-related gene
5, BRCA1, Breast cancer gene 1, CQ, chloroquine, HSP70,
Heat shock protein 70, IHC, Immunohistochemoistry
LAMP2A, Lysosomal membrane associated protein 2 A,
MMC, neu-overexpressing mouse mammary carcinoma,
TNBC, Triple negative breast cancer.

2. Qu X, Yu J, Bhagat G, Furuya N, Hibshoosh H, Troxel A,
Rosen J, Eskelinen EL, Mizushima N, Ohsumi Y, Cattoretti
G, Levine B. Promotion of tumorigenesis by heterozygous
disruption of the beclin 1 autophagy gene. The Journal of
clinical investigation. 2003; 112:1809–1820.
3. Takamura A, Komatsu M, Hara T, Sakamoto A, Kishi
C, Waguri S, Eishi Y, Hino O, Tanaka K, Mizushima N.
Autophagy-deficient mice develop multiple liver tumors.
Genes & development. 2011; 25:795–800.

Author contributions
M.H.M., D.A.G., K.K.P. contributed to the
study’s conception, design, experimental and analytical
performance, and writing of the manuscript. H.F.A.,
L.T-M., T.T., R.C.K., S.J., S.E.B., T.M.S. contributed to
the study’s experimental and analytical performance and
writing of the manuscript. D.B. contributed to statistical
analysis and writing of the manuscript. H.D.B. and M.O.I.
contributed to analytical performance and writing of the
manuscript.

4. Gewirtz DA. The four faces of autophagy: implications for
cancer therapy. Cancer research. 2014; 74:647–651.
5. Mizushima N, Ohsumi Y, Yoshimori T. Autophagosome
formation in mammalian cells. Cell structure and function.
2002; 27:421–429.
6. Abdel-Aziz AK, Shouman S, El-Demerdash E, Elgendy
M, Abdel-Naim AB. Chloroquine synergizes sunitinib
cytotoxicity via modulating autophagic, apoptotic and
angiogenic machineries. Chemico-biological interactions.
2014; 217:28–40.

ACKNOWLEDGMENTS

7. Chen S, Jiang YZ, Huang L, Zhou RJ, Yu KD, Liu Y, Shao
ZM. The residual tumor autophagy marker LC3B serves as
a prognostic marker in local advanced breast cancer after
neoadjuvant chemotherapy. Clinical cancer research. 2013;
19:6853–6862.

We thank Julie Farnsworth for her expertise in
image cytometry and immense dedication to furthering
the research at our institution. We gratefully acknowledge
the support of VCU Massey Cancer Centre and the
Commonwealth Foundation for Cancer Research.

8. Maycotte P, Aryal S, Cummings CT, Thorburn J, Morgan
MJ, Thorburn A. Chloroquine sensitizes breast cancer cells
to chemotherapy independent of autophagy. Autophagy.
2012; 8:200–212.

CONFLICTS OF INTEREST
Authors have no potential conflicts of interest to
disclose.

9. Rangwala R, Leone R, Chang YC, Fecher LA, Schuchter
LM, Kramer A, Tan KS, Heitjan DF, Rodgers G, Gallagher
M, Piao S, Troxel AB, Evans TL, et al. Phase I trial of
hydroxychloroquine with dose-intense temozolomide
in patients with advanced solid tumors and melanoma.
Autophagy. 2014; 10:1369–1379.

FINANCIAL SUPPORT
This work was supported by the Office of the
Assistant Secretary of Defense for Health Affairs through
the Breast Cancer Research Program under Award No.
W81XWH-14-1-0087 (MHM) and W81XWH-14-1-0088
(DAG), and a pilot funding from the VCU Massey Cancer
Center (MHM). Opinions, interpretations, conclusions,
and recommendations are those of the authors and are not
necessarily endorsed by the U.S. Department of Defense.
Services and products in support of the research project
were generated by the VCU Massey Cancer Center Flow
Cytometry Shared Resource, supported, in part, with
funding from the U.S. National Institutes of Health–
National Cancer Institute Cancer Center Support Grant
P30 CA016059.

10. Arcella A, Biagioni F, Antonietta Oliva M, Bucci D, Frati A,
Esposito V, Cantore G, Giangaspero F, Fornai F. Rapamycin
inhibits the growth of glioblastoma. Brain research. 2013;
1495:37–51.
11. Carcereri de Prati A, Butturini E, Rigo A, Oppici E, Rossin
M, Boriero D, Mariotto S. Metastatic Breast Cancer Cells
Enter Into Dormant State and Express Cancer Stem Cells
Phenotype Under Chronic Hypoxia. Journal of cellular
biochemistry. 2017; 118:3237–3248.
12. Santisteban M, Reiman JM, Asiedu MK, Behrens MD, Nassar
A, Kalli KR, Haluska P, Ingle JN, Hartmann LC, Manjili
MH, Radisky DC, Ferrone S, Knutson KL. Immune-induced
epithelial to mesenchymal transition in vivo generates breast
cancer stem cells. Cancer research. 2009; 69:2887–2895.

REFERENCES
1.

13. Cecil DL, Slota M, O’Meara MM, Curtis BC, Gad E, Dang
Y, Herendeen D, Rastetter L, Disis ML. Immunization
against HIF-1alpha Inhibits the Growth of Basal Mammary

Galluzzi L, Pietrocola F, Bravo-San Pedro JM, Amaravadi
RK, Baehrecke EH, Cecconi F, Codogno P, Debnath J,

www.oncotarget.com

9

Oncotarget

Tumors and Targets Mammary Stem Cells in vivo. Clinical
cancer research. 2017; 23:3396–3404.

inhibition of tumorigenesis by beclin 1. Nature. 1999;
402:672–676.

14. Zeng X, Kinsella TJ. Impact of Autophagy on Chemotherapy
and Radiotherapy Mediated Tumor Cytotoxicity: “To Live
or not to Live”. Frontiers in oncology. 2011; 1:30.

24. Ladoire S, Penault-Llorca F, Senovilla L, Dalban C, Enot D,
Locher C, Prada N, Poirier-Colame V, Chaba K, Arnould L,
Ghiringhelli F, Fumoleau P, Spielmann M, et al. Combined
evaluation of LC3B puncta and HMGB1 expression
predicts residual risk of relapse after adjuvant chemotherapy
in breast cancer. Autophagy. 2015; 11:1878–1890.

15. Shen S, Kepp O, Michaud M, Martins I, Minoux H,
Metivier D, Maiuri MC, Kroemer RT, Kroemer G.
Association and dissociation of autophagy, apoptosis and
necrosis by systematic chemical study. Oncogene. 2011;
30:4544–4556.

25. Wang L, Yao L, Zheng YZ, Xu Q, Liu XP, Hu X, Wang
P, Shao ZM. Expression of autophagy-related proteins
ATG5 and FIP200 predicts favorable disease-free survival
in patients with breast cancer. Biochemical and biophysical
research communications. 2015; 458:816–822.

16. Sosa MS, Bragado P, Debnath J, Aguirre-Ghiso
JA. Regulation of tumor cell dormancy by tissue
microenvironments and autophagy. Advances in Experimental
Medicine and Biology. 2013; 734:73–89.

26. Sun AG, Meng FG, Wang MG. CISD2 promotes the
proliferation of glioma cells via suppressing beclin1mediated
autophagy and is targeted by microRNA449a. Molecular
medicine reports. 2017; 16:7939–7948.

17. Payne KK, Keim RC, Graham L, Idowu MO, Wan W,
Wang XY, Toor AA, Bear HD, Manjili MH. Tumor-reactive
immune cells protect against metastatic tumor and induce
immunoediting of indolent but not quiescent tumor cells.
Journal of leukocyte biology. 2016.

27. Kmieciak M, Knutson KL, Dumur CI, Manjili MH. HER2/neu antigen loss and relapse of mammary carcinoma are
actively induced by T cell-mediated anti-tumor immune
responses. European journal of immunology. 2007; 37:
675–685.

18. Liang DH, Choi DS, Ensor JE, Kaipparettu BA, Bass BL,
Chang JC. The autophagy inhibitor chloroquine targets
cancer stem cells in triple negative breast cancer by
inducing mitochondrial damage and impairing DNA break
repair. Cancer letters. 2016; 376:249–258.

28. Guy CT, Webster MA, Schaller M, Parsons TJ, Cardiff RD,
Muller WJ. Expression of the neu protooncogene in the
mammary epithelium of transgenic mice induces metastatic
disease. Proceedings of the National Academy of Sciences
of the United States of America. 1992; 89:10578–10582.

19. Choi DS, Blanco E, Kim YS, Rodriguez AA, Zhao H,
Huang TH, Chen CL, Jin G, Landis MD, Burey LA, Qian
W, Granados SM, Dave B, et al. Chloroquine eliminates
cancer stem cells through deregulation of Jak2 and DNMT1.
Stem cells (Dayton, Ohio). 2014; 32:2309–2323.

29. Kmieciak M, Morales JK, Morales J, Bolesta E, Grimes M,
Manjili MH. Danger signals and nonself entity of tumor
antigen are both required for eliciting effective immune
responses against HER-2/neu positive mammary carcinoma:
implications for vaccine design. Cancer immunology,
immunotherapy: CII. 2008; 57:1391–1398.

20. Karantza-Wadsworth V, Patel S, Kravchuk O, Chen G,
Mathew R, Jin S, White E. Autophagy mitigates metabolic
stress and genome damage in mammary tumorigenesis.
Genes & development. 2007; 21:1621–1635.

30. Kmieciak M, Basu D, Payne KK, Toor A, Yacoub A, Wang
XY, Smith L, Bear HD, Manjili MH. Activated NKT cells
and NK cells render T cells resistant to myeloid-derived
suppressor cells and result in an effective adoptive cellular
therapy against breast cancer in the FVBN202 transgenic
mouse. Journal of immunology (Baltimore, Md.: 1950).
2011; 187:708–717.

21. Mathew R, Kongara S, Beaudoin B, Karp CM, Bray
K, Degenhardt K, Chen G, Jin S, White E. Autophagy
suppresses tumor progression by limiting chromosomal
instability. Genes & development. 2007; 21:1367–1381.
22. Mizushima N, Levine B, Cuervo AM, Klionsky DJ.
Autophagy fights disease through cellular self-digestion.
Nature. 2008; 451:1069–1075.
23. Liang XH, Jackson S, Seaman M, Brown K, Kempkes
B, Hibshoosh H, Levine B. Induction of autophagy and

www.oncotarget.com

10

Oncotarget

